Log in

Relevant bibliographies by topics / Watch and wait / Journal articles

To see the other types of publications on this topic, follow the link: Watch and wait.

Journal articles on the topic 'Watch and wait'

Author: Grafiati

Published: 4 May 2024

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 50 journal articles for your research on the topic 'Watch and wait.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.

1

Dunnion, Claire, Martina Giltenane, and Maura Dowling. "The ‘inbetweeners’: living on a watch and wait approach for chronic lymphocytic leukaemia – a qualitative study." British Journal of Nursing 32, no. 16 (September 7, 2023): 794–800. http://dx.doi.org/10.12968/bjon.2023.32.16.794.

Full text

Abstract:

Background: Chronic lymphocytic leukaemia (CLL) is an incurable disease; many people with the condition do not require active treatment and are monitored using a watch and wait approach. Aim: The aim of this study was to explore the experiences of people living with a diagnosis of CLL and on watch and wait. Methods: Using a descriptive qualitative approach, seven participants on the watch and wait approach were interviewed. Data analysis was guided by systematic text condensation. Findings: Participants reported anxiety, referring to ‘wait and worry’. Their information needs were not met, and they resorted to seeking information on possible future treatments themselves. They also experienced feeling like an imposter because they were not receiving active treatment like other patients with cancer. Conclusions: A greater understanding of how information provision affects levels of anxiety and worry among people living with CLL on watch and wait is needed. In addition, clinical nurse specialists could deliver education on the watch and wait approach, supplemented by video-based educational materials developed by the haematology team.

APA, Harvard, Vancouver, ISO, and other styles

2

Byun, Hwa Kyung, and Woong Sub Koom. "A practical review of watch-and-wait approach in rectal cancer." Radiation Oncology Journal 41, no. 1 (March 31, 2023): 4–11. http://dx.doi.org/10.3857/roj.2023.00038.

Full text

Abstract:

Rectal resection surgery after neoadjuvant treatment has been the mainstay treatment of locally advanced rectal cancer. However, functional outcomes and quality of life after radical resection of the rectum remain suboptimal. The excellent oncologic outcomes in patients who achieved pathologic complete response after neoadjuvant treatment questioned the need for radical surgery. The watch-and-wait approach is a noninvasive therapeutic alternative for organ preservation and avoiding operative morbidity. In the watch-and-wait approach, patients with locally advanced rectal cancer who achieve excellent clinical response after neoadjuvant treatment undergo active surveillance rather than rectal cancer surgery. In this practical review, we summarized the main results of studies on the watch-and-wait approach and provided a practical method for implementing the watch-and-wait approach.

APA, Harvard, Vancouver, ISO, and other styles

3

Kassirer, Jerome P., and Richard I. Kopelman. "Watch and Wait, or Operate?" Hospital Practice 20, no. 10 (October 15, 1985): 75–85. http://dx.doi.org/10.1080/21548331.1985.11703161.

Full text

APA, Harvard, Vancouver, ISO, and other styles

4

LEPKOWSKI, WIL. "JAPAN WATCHERS WATCH AND WAIT." Chemical & Engineering News 76, no. 22 (June 1998): 35–41. http://dx.doi.org/10.1021/cen-v076n022.p035.

Full text

APA, Harvard, Vancouver, ISO, and other styles

5

Kallam, Avyakta, and James O. Armitage. "Watch and Wait, Salvage Later." International Journal of Radiation Oncology*Biology*Physics 100, no. 3 (March 2018): 549–50. http://dx.doi.org/10.1016/j.ijrobp.2017.11.007.

Full text

APA, Harvard, Vancouver, ISO, and other styles

6

Harder, Ben. "Watch and Wait, or Not." Science News 167, no. 20 (May 14, 2005): 309. http://dx.doi.org/10.2307/4016223.

Full text

APA, Harvard, Vancouver, ISO, and other styles

7

Kim, Mia, and Christoph-Thomas Germer. "Organerhalt Rektum – „watch and wait“." coloproctology 42, no. 4 (July 10, 2020): 302–8. http://dx.doi.org/10.1007/s00053-020-00475-4.

Full text

APA, Harvard, Vancouver, ISO, and other styles

8

Lins Neto, Manoel Álvaro de Freitas, Luís Henrique Alves Salvador Filho, Jorge Artur Peçanha de Miranda Coelho, and João Otávio de Moraes Rolim. "Watch and Wait, Worth It?" Journal of Coloproctology 42, no. 04 (December 2022): 308–14. http://dx.doi.org/10.1055/s-0042-1758206.

Full text

Abstract:

Abstract Background The surgery with total mesorectal excision recommended by R. J. Heald in 1982 is the gold standard. Rectal cancer (RC) surgery has a morbidity rate ranging from 6 to 35%, and it can cause functional issues such as sexual, urinary, and bowel dysfunction in the long term. Neoadjuvant chemoradiotherapy (CRT) has been gaining ground in patients with lesions in the middle and lower rectum. The aim of the present study is to present the experience of a reference service in the treatment of RC. Patients and Methods A retrospective study involving 53 patients diagnosed with RC between January 2017 and December 2019 with follow-up until December 2020. We examined tumor location, disease stage, digital rectal exam findings, carcinoembryonic antigen (CEA), therapeutic modality offered, and follow-up time. Results A total of 32% of the patients were men and 68% were women, with a mean age of 60 years old. Location: upper rectum in 6 cases, middle rectum in 21 cases, and lower rectum in 26 cases with evolution from 9.8 to 13.5 months. The most frequent complaints were hematochezia and constipation. A total of 36 patients underwent neoadjuvant therapy: 11 complete clinical response (CCR) (30.5%), 20 (55.5%) partial clinical response (PCR), and no response in 5 patients (14%). The follow-up ranged from 12 to 48 months, with a mean of 30.5 months. A total of 25% of the patients had RC that went beyond the mesorectal fascia, and 22.64% had metastases in other parts of the body when they were diagnosed. Conclusion Neoadjuvant radio and chemotherapy present themselves as an alternative in the treatment of rectal cancer. In 36 patients, 30.5% had a complete clinical response, 55.5% had a partial clinical response, and 14% had no response. It was worth doing the “Watch and Wait” (W&W) to sample. A definitive colostomy was avoided. However, it is necessary to expand the study to a larger follow-up and more patients. Additionally, it is necessary to implement a multicenter study.

APA, Harvard, Vancouver, ISO, and other styles

9

Kalasauskas, Darius, Naureen Keric, Salman Abu Ajaj, Leoni von Cube, Florian Ringel, and Mirjam Renovanz. "Psychological Burden in Meningioma Patients under a Wait-and-Watch Strategy and after Complete Resection Is High—Results of a Prospective Single Center Study." Cancers 12, no. 12 (November 25, 2020): 3503. http://dx.doi.org/10.3390/cancers12123503.

Full text

Abstract:

The diagnosis of intracranial meningiomas as incidental findings is increasing by growing availability of MRI diagnostics. However, the psychological distress of patients with incidental meningiomas under a wait-and-watch strategy is unknown. Therefore, we aimed to compare the psychosocial situation of meningioma patients under wait-and-watch to patients after complete resection to bridge this gap. The inclusion criteria for the prospective monocenter study were either an incidental meningioma under a wait-and-watch strategy or no neurologic deficits after complete resection. Sociodemographic, clinical, and health-related quality of life and clinical data were assessed. Psychosocial factors were measured by the Distress Thermometer (DT), Hospital Anxiety and Depression Scale (HADS), Brief Fatigue Inventory (BFI), and the Short Form (SF-36). A total of 62 patients were included (n = 51 female, mean age 61 (SD 13) years). According to HADS, the prevalence of anxiety was 45% in the postoperative and 42% in the wait-and-watch group (p = 0.60), and depression was 61% and 87%, respectively (p = 0.005). In total, 43% of patients under wait-and-watch and 37% of patients in the postoperative group scored ≥6 on the DT scale. SF-36 scores were similar in all categories except general health (p = 0.005) and physical component aggregate score (43.7 (13.6) vs. 50.5 (9.5), (p = 0.03), both lower in the wait-and-watch group. Multivariate analysis revealed the wait-and-watch strategy was associated with a 4.26-fold higher risk of a pathological depression score based on HADS (p = 0.03). This study demonstrates a high prevalence of psychological distress in meningioma patients. Further evaluation is necessary to identify the patients in need of psychooncological support.

APA, Harvard, Vancouver, ISO, and other styles

10

Ansell, Stephen M. "Follicular lymphoma: watch and wait is watch and worry." Lancet Oncology 15, no. 4 (April 2014): 368–69. http://dx.doi.org/10.1016/s1470-2045(14)70066-x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

11

Weiser, Martin R., Joanne F. Chou, Jin K. Kim, Maria Widmar, Iris H. Wei, Emmanouil P. Pappou, J. Joshua Smith, et al. "A Dynamic Clinical Calculator for Estimating Conditional Recurrence-Free Survival After Total Neoadjuvant Therapy for Rectal Cancer and Either Surgery or Watch-and-Wait Management." JAMA Network Open 5, no. 9 (September 29, 2022): e2233859. http://dx.doi.org/10.1001/jamanetworkopen.2022.33859.

Full text

Abstract:

ImportanceThe risk of recurrence in patients with locally advanced rectal cancer has historically been determined after surgery, relying on pathologic variables. A growing number of patients are being treated without surgery, and their risk of recurrence needs to be calculated differently.ObjectiveTo develop a dynamic calculator for estimating the probability of recurrence-free survival (RFS) in patients with rectal cancer who undergo total neoadjuvant therapy (TNT) (induction systemic chemotherapy and chemoradiotherapy) and either surgery or watch-and-wait management.Design, Setting, and ParticipantsThis cohort study included patients who presented with stage II or III rectal cancer between June 1, 2009, and March 1, 2015, at a comprehensive cancer center. Conditional modeling was incorporated into a previously validated clinical calculator to allow the probability of RFS to be updated based on whether the patient remained in watch-and-wait management or underwent delayed surgery. Data were analyzed from November 2021 to March 2022.ExposureTNT followed by immediate surgery or watch-and-wait management with the possibility of delayed surgery.Main Outcomes and MeasuresRFS, concordance index, calibration curves.ResultsOf the 302 patients in the cohort, 204 (68%) underwent surgery within 3 months from TNT completion (median [range] age, 51 [22-82] years; 78 [38%] women), 54 (18%) underwent surgery more than 3 months from TNT completion (ie, delayed surgery; median [range] age, 62 [31-87] years; 30 [56%] female), and 44 (14%) remained in watch-and-wait management as of April 21, 2021 (median [range] age, 58 [32-89] years; 16 [36%] women). Among patients who initially opted for watch-and-wait management, migration to surgery due to regrowth or patient choice occurred mostly within the first year following completion of TNT, and RFS did not differ significantly whether surgery was performed 3.0 to 5.9 months (73%; 95% CI, 52%-92%) vs 6.0 to 11.9 months (71%; 95% CI, 51%-99%) vs more than 12.0 months (70%; 95% CI, 49%-100%) from TNT completion (P = .70). RFS for patients in the watch-and-wait cohort at 12 months from completion of TNT more closely resembled patients who had undergone surgery and had a pathologic complete response than the watch-and-wait cohort at 3 months from completion of TNT. Accordingly, model performance improved over time, and the concordance index increased from 0.62 (95% CI, 0.53-0.71) at 3 months after TNT to 0.66 (95% CI, 0-0.75) at 12 months.Conclusions and RelevanceIn this cohort study of patients with rectal cancer, the clinical calculator reliably estimated the likelihood of RFS for patients who underwent surgery immediately after TNT, patients who underwent delayed surgery after entering watch-and-wait management, and patients who remained in watch-and-wait management. Delayed surgery following attempted watch-and-wait did not appear to compromise oncologic outcomes. The risk calculator provided conditional survival estimates at any time during surveillance and could help physicians counsel patients with rectal cancer about the consequences of alternative treatment pathways and thereby support informed decisions that incorporate patients’ preferences.

APA, Harvard, Vancouver, ISO, and other styles

12

&NA;. "Wait and watch in prostate cancer." Inpharma Weekly &NA;, no. 889 (May 1993): 11. http://dx.doi.org/10.2165/00128413-199308890-00023.

Full text

APA, Harvard, Vancouver, ISO, and other styles

13

Ibrahim, Mounir, Shashank Sarvepalli, Gareth Morris-Stiff, Maged Rizk, Amit Bhatt, R. Matthew Walsh, Umar Hayat, Ari Garber, John Vargo, and Carol A. Burke. "Gallstones: Watch and wait, or intervene?" Cleveland Clinic Journal of Medicine 85, no. 4 (April 2018): 323–31. http://dx.doi.org/10.3949/ccjm.85a.17035.

Full text

APA, Harvard, Vancouver, ISO, and other styles

14

Studer, U. E., G. Thalmann, and E. J. Zingg. "Radical Prostatectomy or Wait-and-Watch?" European Urology 24, no. 2 (1993): 24–28. http://dx.doi.org/10.1159/000474384.

Full text

APA, Harvard, Vancouver, ISO, and other styles

15

Singh, N. K. "Universal Basic Income: Wait and Watch." Indian Journal of Human Development 11, no. 2 (August 2017): 197–99. http://dx.doi.org/10.1177/0973703017738665.

Full text

APA, Harvard, Vancouver, ISO, and other styles

16

Goodman, Karyn A. "Definitive Chemoradiotherapy (“Watch-and-Wait” Approach)." Seminars in Radiation Oncology 26, no. 3 (July 2016): 205–10. http://dx.doi.org/10.1016/j.semradonc.2016.02.003.

Full text

APA, Harvard, Vancouver, ISO, and other styles

17

Schumacher, Beate. "Watch-and-wait nach neoadjuvanter RCT." Gastro-News 6, no. 1 (February 2019): 62. http://dx.doi.org/10.1007/s15036-019-0541-4.

Full text

APA, Harvard, Vancouver, ISO, and other styles

18

LeBlanc, Thomas, Arif Kamal, and Amy Abernethy. "Rituximab for follicular lymphoma: watch and wait, watch and worry, or watch and live?" Lancet Oncology 15, no. 7 (June 2014): e251-e252. http://dx.doi.org/10.1016/s1470-2045(14)70215-3.

Full text

APA, Harvard, Vancouver, ISO, and other styles

19

Smith, J. Joshua, Philip B. Paty, and Julio Garcia-Aguilar. "Watch and Wait in Rectal Cancer or More Wait and See?" JAMA Surgery 155, no. 7 (July 1, 2020): 657. http://dx.doi.org/10.1001/jamasurg.2020.0226.

Full text

APA, Harvard, Vancouver, ISO, and other styles

20

Armitage, James O., and Dan L. Longo. "Is watch and wait still acceptable for patients with low-grade follicular lymphoma?" Blood 127, no. 23 (June 9, 2016): 2804–8. http://dx.doi.org/10.1182/blood-2015-11-632745.

Full text

Abstract:

Abstract Follicular lymphoma (FL) represents more than 20% of all non-Hodgkin lymphomas worldwide and approximately 30% of the non-Hodgkin lymphomas diagnosed in the United States. Although occasionally localized at the time of diagnosis, most patients have disseminated disease. However, patients are frequently asymptomatic, and this, in combination with a long median survival, led to the initial studies of observing asymptomatic patients without initial therapy, ie, “watch and wait.” Since the initial report of watch and wait as a treatment strategy for patients with low-grade FL, our understanding of the biology of the disease has advanced; multiple active new agents have been introduced into practice, and the survival of patients with low-grade FL has improved. Given these changes, is watch and wait still an acceptable treatment recommendation for a newly diagnosed patient with low-grade FL?

APA, Harvard, Vancouver, ISO, and other styles

21

Silva, Lázaro de Souza, Thaís Loth Marton Azzi, Alice Maciel De Lacerda, Danielle Emenegildo Valbusa, and Guilherme Augusto Alves Pizani. "Abordagem "watch and wait" no tratamento de Câncer Colorretal: análise e perspectivas sob a ótica de uma revisão integrativa." Brazilian Journal of Health Review 6, no. 5 (September 19, 2023): 22231–37. http://dx.doi.org/10.34119/bjhrv6n5-259.

Full text

Abstract:

Introdução: O tratamento do câncer retal evoluiu nas últimas décadas, com cirurgia sendo o padrão-ouro, mas associada a morbidades. Abordagens minimamente invasivas não reduzem a morbidade. A preservação de órgãos, como "watch and wait," é considerada em casos selecionados. O câncer colorretal é comum globalmente, com altas taxas de incidência e mortalidade, relacionadas a fatores genéticos e ambientais. Lesões pequenas podem ser tratadas com excisão local, mas a maioria requer cirurgia transabdominal. Excisão local após quimio e radio terapias podem ser uma opção segura. A estratégia "watch and wait" é uma alternativa segura para pacientes com remissão clínica completa após terapia neoadjuvante, especialmente em casos avançados. Metodologia: Foi conduzida uma revisão da literatura sobre o tratamento do câncer de colo retal usando a abordagem "watch and wait". Os descritores "watch and wait and rectal cancer" foram usados para pesquisar nas bases de dados PubMed e Scielo, resultando em vários estudos. A seleção incluiu apenas estudos completos em português e inglês publicados entre 2014 e 2023, excluindo pesquisas anteriores, resumos incompletos e artigos menos relevantes. Após a seleção, 08 estudos foram analisados para embasar este artigo, abrangendo revisões sistemáticas e estudos de coorte com diferentes abordagens metodológicas. Desenvolvimento: O câncer colorretal é tratado tradicionalmente com cirurgia, radioterapia e quimioterapia. No entanto, a abordagem "Watch and Wait" é uma alternativa conservadora para pacientes com resposta completa à terapia neoadjuvante, estágio inicial e ausência de metástases. Um comitê multidisciplinar avalia a adequação dessa estratégia com base em critérios de resposta e imagem. Os benefícios incluem preservação da função do órgão e qualidade de vida, mas desafios incluem avaliação precisa da resposta e acompanhamento a longo prazo. A educação dos pacientes e profissionais é crucial. A "Watch and Wait" é uma perspectiva promissora no tratamento do câncer colorretal, desafiando a abordagem cirúrgica imediata. Conclusão: Dada a persistência do câncer colorretal como um desafio de saúde global, a pesquisa contínua e a adoção de abordagens baseadas em evidências são essenciais para avançar na luta contra essa doença e oferecer aos pacientes a melhor qualidade de vida possível, ao mesmo tempo em que se busca reduzir o impacto do câncer retal na sociedade como um todo.

APA, Harvard, Vancouver, ISO, and other styles

22

Russell, Katie, Anna Tickle, Nima Moghaddam, and Sanchia Biswas. "Exploring the Psychosocial Needs of Adults with Haematological Cancer under Watch-and-Wait: A Qualitative Study." European Journal of Cancer Care 2023 (October 30, 2023): 1–10. http://dx.doi.org/10.1155/2023/6653645.

Full text

Abstract:

Objective. Research reporting the unmet needs of individuals with haematological cancers under watch-and-wait is scarce, despite reports of elevated levels of psychological distress. This qualitative study aimed to explore the psychosocial needs of these individuals, and when these were met, if so at all. Methods. A longitudinal design using semistructured interviews was used. Individuals with a diagnosis of haematological cancer living under watch-and-wait were recruited through online support groups. Participants were each invited to two semistructured interviews, six months apart. Interviews took place in March 2022 and September 2022 and were therefore in the context of the COVID-19 pandemic. All interviews were recorded and transcribed verbatim. Reflexive thematic analysis and pattern-oriented longitudinal analysis were used to analyse the data. Results. Of the fifteen participants interviewed initially, twelve attended a second interview. The sample was predominantly White and female. Across participants and time points, a theme was generated that individuals experienced a “Psychological battle of watch-and-wait.” Under this overarching theme, four themes were constructed: “Understanding the impossible: Cancer that does not require treatment;” “Sense of abandonment under watch and wait;” “The importance of peer connection;” and “Trying to live after COVID-19.” The themes were understood to predominantly represent needs for information, communication, peer support, and emotional support and were most often met when individuals engaged with relevant charities. Conclusion. People living with haematological cancer under watch-and-wait may be at risk of having unmet needs across domains, and without support, these needs will likely remain unmet over time. The findings add to the growing literature base how Oncology and Haematology services can holistically support individuals with indolent cancers to live well alongside their diagnosis.

APA, Harvard, Vancouver, ISO, and other styles

23

&NA;. "Seize the day or wait and watch?" Inpharma Weekly &NA;, no. 971 (January 1995): 4. http://dx.doi.org/10.2165/00128413-199509710-00004.

Full text

APA, Harvard, Vancouver, ISO, and other styles

24

&NA;, &NA;. "Asymptomatic Bacteriuria In Elders: Watch and Wait." AJN, American Journal of Nursing 95, no. 9 (September 1995): 54. http://dx.doi.org/10.1097/00000446-199509000-00023.

Full text

APA, Harvard, Vancouver, ISO, and other styles

25

Chang, George J. "Simulating Watch and Wait for Rectal Cancer." Diseases of the Colon & Rectum 58, no. 2 (February 2015): 155–56. http://dx.doi.org/10.1097/dcr.0000000000000280.

Full text

APA, Harvard, Vancouver, ISO, and other styles

26

George, S. "Barrett's high-grade dysplasia: wait and watch?,." American Journal of Gastroenterology 97, no. 10 (October 2002): 2674–75. http://dx.doi.org/10.1016/s0002-9270(02)05452-7.

Full text

APA, Harvard, Vancouver, ISO, and other styles

27

Bujko, Krzysztof, and Wojciech Michalski. "Watch-and-wait strategy in rectal cancer." Lancet Gastroenterology & Hepatology 4, no. 2 (February 2019): 96–97. http://dx.doi.org/10.1016/s2468-1253(18)30416-3.

Full text

APA, Harvard, Vancouver, ISO, and other styles

28

Lynch, Sherry. "Families can watch surgery while they wait." AORN Journal 46, no. 3 (September 1987): 522–27. http://dx.doi.org/10.1016/s0001-2092(07)66464-3.

Full text

APA, Harvard, Vancouver, ISO, and other styles

29

Lee, Christina, and Peter Martin. "Watch and Wait in Mantle Cell Lymphoma." Hematology/Oncology Clinics of North America 34, no. 5 (October 2020): 837–47. http://dx.doi.org/10.1016/j.hoc.2020.06.002.

Full text

APA, Harvard, Vancouver, ISO, and other styles

30

Shoham, Shmuel. "Cytomegalovirus: Prophylaxis, preemption, or “Wait and Watch”." Liver Transplantation 19, no. 1 (December 12, 2012): 108. http://dx.doi.org/10.1002/lt.23564.

Full text

APA, Harvard, Vancouver, ISO, and other styles

31

Cerdan-Santacruz, Carlos, Guilherme Pagin São Julião, Bruna Borba Vailati, Leonardo Corbi, Angelita Habr-Gama, and Rodrigo Oliva Perez. "Watch and Wait Approach for Rectal Cancer." Journal of Clinical Medicine 12, no. 8 (April 14, 2023): 2873. http://dx.doi.org/10.3390/jcm12082873.

Full text

Abstract:

The administration of neoadjuvant chemoradiotherapy (nCRT) followed by total mesorrectal excision (TME) and selective use of adjuvant chemotherapy can still be considered the standard of care in locally advanced rectal cancer (LARC). However, avoiding sequelae of TME and entering a narrow follow-up program of watch and wait (W&W), in select cases that achieve a comparable clinical complete response (cCR) to nCRT, is now very attractive to both patients and clinicians. Many advances based on well-designed studies and long-term data coming from big multicenter cohorts have drawn some important conclusions and warnings regarding this strategy. In order to safely implement W&W, it is important consider proper selection of cases, best treatment options, surveillance strategy and the attitudes towards near complete responses or even tumor regrowth. The present review offers a comprehensive overview of W&W strategy from its origins to the most current literature, from a practical point of view focused on daily clinical practice, without losing sight of the most important future prospects in this area.

APA, Harvard, Vancouver, ISO, and other styles

32

Geubels, Barbara, Aart-Jan van den Esschert, Koen Peeters, Per Nilsson, Geerard Beets, and Brechtje Grotenhuis. "Outcomes of Watch-and-Wait after short-course radiotherapy in the Dutch and International Watch-and-Wait registry." European Journal of Surgical Oncology 50, no. 2 (February 2024): 107339. http://dx.doi.org/10.1016/j.ejso.2023.107339.

Full text

APA, Harvard, Vancouver, ISO, and other styles

33

Bahadoer, Renu R., Koen C. M. J. Peeters, Geerard L. Beets, Nuno L. Figueiredo, Esther Bastiaannet, Alexander Vahrmeijer, Sofieke J. D. Temmink, et al. "Watch and wait after a clinical complete response in rectal cancer patients younger than 50 years." British Journal of Surgery 109, no. 1 (November 5, 2021): 114–20. http://dx.doi.org/10.1093/bjs/znab372.

Full text

Abstract:

Abstract Background Young-onset rectal cancer, in patients less than 50 years, is expected to increase in the coming years. A watch-and-wait strategy is nowadays increasingly practised in patients with a clinical complete response (cCR) after neoadjuvant treatment. Nevertheless, there may be reluctance to offer organ preservation treatment to young patients owing to a potentially higher oncological risk. This study compared patients aged less than 50 years with those aged 50 years or more to identify possible differences in oncological outcomes of watch and wait. Methods The study analysed data from patients with a cCR after neoadjuvant therapy in whom surgery was omitted, registered in the retrospective–prospective, multicentre International Watch & Wait Database (IWWD). Results In the IWWD, 1552 patients met the inclusion criteria, of whom 199 (12.8 per cent) were aged less than 50 years. Patients younger than 50 years had a higher T category of disease at diagnosis (P = 0.011). The disease-specific survival rate at 3 years was 98 (95 per cent c.i. 93 to 99) per cent in this group, compared with 97 (95 to 98) per cent in patients aged over 50 years (hazard ratio (HR) 1.67, 95 per cent c.i. 0.76 to 3.64; P = 0.199). The cumulative probability of local regrowth at 3 years was 24 (95 per cent c.i. 18 to 31) per cent in patients less than 50 years and 26 (23 to 29) per cent among those aged 50 years or more (HR 1.09, 0.79 to 1.49; P = 0.603). Both groups had a cumulative probability of distant metastases of 10 per cent at 3 years (HR 1.00, 0.62 to 1.62; P = 0.998). Conclusion There is no additional oncological risk in young patients compared with their older counterparts when following a watch-and-wait strategy after a cCR. In light of a shared decision-making process, watch and wait should be also be discussed with young patients who have a cCR after neoadjuvant treatment.

APA, Harvard, Vancouver, ISO, and other styles

34

Levin, T. "Quality of life, depression and anxiety in chronic lymphocytic leukemia during phases of “watchful waiting” and active treatment." Journal of Clinical Oncology 24, no. 18_suppl (June 20, 2006): 6603. http://dx.doi.org/10.1200/jco.2006.24.18_suppl.6603.

Full text

Abstract:

6603 Background: Although chronic lymphocytic leukemia (CLL) accounts for 25–30% of leukemia cases in the USA, little is known about its quality of life (QOL) and psychosocial burden. The purpose of this study was to compare QOL, anxiety and depression in watch and wait versus actively treated CLL. Methods: Using a cross-sectional design, 105 patients were recruited from a CLL research database. 57 were classified as watch and wait and 48 as receiving or having received chemotherapy for CLL. The patients completed a battery of QOL measures including the SF-36, FACT-Lym, Beck Depression Inventory (BDI-II), Beck Anxiety Inventory (BAI) and the Patient Health Questionnaire. Results: No differences were found between the treatment groups on the main QOL outcome measures - Mental Component Score, Physical Component Score, FACT-G, FACT-lymphoma (15 item), BDI-II and BAI. There was a clear age effect: younger patients (<60 years old) have worse Mental Component (p=0.0001), FACT-G (p=0.060), depression (p=0.014), Role Emotional (p=0.042), Mental Health (p=0.001), FACT-Emotional (p=0.0001) and FACT-Social (p=0.002) scores. Younger watch and wait patients seem to be particularly vulnerable to anxiety (p=0.052). Social and emotional QOL are statistically similar in both newly diagnosed and patients diagnosed six or more years ago, although patients do carry a greater physical QOL burden with time (p=0.05). Conclusions: Overall QOL, depression and anxiety are remarkably similar in watch and wait versus actively treated CLL, despite the latter group having, by definition, later stage disease. Younger patients (<60 years old) seem particularly vulnerable to having a reduced emotional and social QOL and having more depression. Younger watch and wait patients stood out as suffering from more anxiety. Patients diagnosed for more than 6 years carry a greater physical QOL burden, but social and emotional QOL are similar to newly diagnosed patients. Implications of these findings are considered. [Table: see text] No significant financial relationships to disclose.

APA, Harvard, Vancouver, ISO, and other styles

35

On, J., J. Shim, and EH Aly. "Systematic review and meta-analysis on outcomes of salvage therapy in patients with tumour recurrence during ‘watch and wait’ in rectal cancer." Annals of The Royal College of Surgeons of England 101, no. 7 (September 2019): 441–52. http://dx.doi.org/10.1308/rcsann.2019.0018.

Full text

Abstract:

Introduction The ‘watch and wait’ approach has recently emerged as an alternative approach for managing patients with complete clinical response in rectal cancer. However, less is understood whether the intervention is associated with a favourable outcome among patients who require salvage therapy following local recurrence. Materials and methods A comprehensive systematic search was performed using EMBASE, PubMed, MEDLINE, Journals@Ovid as well as hand searches; published between 2004 and 2018, to identify studies where outcomes of patients undergoing watch and wait were compared with conventional surgery. Study quality was assessed using the Newcastle–Ottawa assessment scale. The main outcome was relative risks for overall and disease specific mortality in salvage therapy. Results Nine eligible studies were included in the meta-analysis. Of 248 patients who followed the watch and wait strategy, 10.5% had salvage therapy for recurrent disease. No statistical heterogeneity was found in the results. The relative risk of overall mortality in the salvage therapy group was 2.42 (95% confidence interval 0.96–6.13) compared with the group who had conventional surgery, but this was not statistically significant (P > 0.05). The relative risk of disease specific mortality in salvage therapy was 2.63 (95% confidence interval 0.81–8.53). Conclusion Our findings demonstrated that there was no significant difference in overall and disease specific mortality in patients who had salvage treatment following recurrence of disease in the watch and wait group compared with the standard treatment group. However, future research into the oncological safety of salvage treatment is needed.

APA, Harvard, Vancouver, ISO, and other styles

36

Penchev, D., S. Maslyankov, V. Kostov, L. Dimitrova, V. Ivanova, and GTodorov GTodorov. "WATCH AND WAIT APPROACH IN RECTAL CANCER TREATMENT." International Journal of Surgery and Medicine 2, no. 1 (2016): 39. http://dx.doi.org/10.5455/ijsm.20150819025133.

Full text

APA, Harvard, Vancouver, ISO, and other styles

37

Mullaney, Tamara G., Amy L. Lightner, Michael Johnston, James Keck, and David Wattchow. "‘Watch and wait’ after chemoradiotherapy for rectal cancer." ANZ Journal of Surgery 88, no. 9 (July 25, 2018): 836–41. http://dx.doi.org/10.1111/ans.14352.

Full text

APA, Harvard, Vancouver, ISO, and other styles

38

Carlson, Robert H. "Follicular Lymphoma: Time to Reevaluate ‘Watch and Wait’?" Oncology Times 32, no. 22 (November 2010): 22. http://dx.doi.org/10.1097/01.cot.0000391432.65745.e0.

Full text

APA, Harvard, Vancouver, ISO, and other styles

39

Enea, Ned A., and Mark D. Swank. "Hemodialysis Graft Declotting: “Lyse and Wait” and Watch." Journal of Vascular and Interventional Radiology 9, no. 4 (July 1998): 660–61. http://dx.doi.org/10.1016/s1051-0443(98)70341-0.

Full text

APA, Harvard, Vancouver, ISO, and other styles

40

BOSCHERT, SHERRY. "Watch and Wait With Small, Simple Ovarian Cysts." Internal Medicine News 39, no. 7 (April 2006): 14. http://dx.doi.org/10.1016/s1097-8690(06)73230-9.

Full text

APA, Harvard, Vancouver, ISO, and other styles

41

McClain, Kenneth L., and Caridad A. Martinez. "HLH: watch and wait, or act and cure?" Blood 132, no. 19 (November 8, 2018): 2005–6. http://dx.doi.org/10.1182/blood-2018-09-873646.

Full text

APA, Harvard, Vancouver, ISO, and other styles

42

Thomas, Charles R. "Is Watch-and-Wait Ready for Prime Time?" JAMA Oncology 5, no. 4 (April 11, 2019): e185895. http://dx.doi.org/10.1001/jamaoncol.2018.5895.

Full text

APA, Harvard, Vancouver, ISO, and other styles

43

Fra-Fernández, Sara, Luis Gorospe-Sarasúa, Alberto Cabañero-Sánchez, Gemma Muñoz-Molina, Usue Caballero-Silva, and Nicolás Moreno-Mata. "Subsolid pulmonary nodules: why not “watch and wait”?" Annals of Translational Medicine 12, no. 1 (February 2024): 3. http://dx.doi.org/10.21037/atm-23-1794.

Full text

APA, Harvard, Vancouver, ISO, and other styles

44

Kitamura, Tadashi, Shinzo Torii, Takashi Miyamoto, Toshiaki Mishima, Hirotoki Ohkubo, Shunichiro Fujioka, Kazuki Yakuwa, et al. "Watch-and-wait strategy for type A intramural haematoma and acute aortic dissection with thrombosed false lumen of the ascending aorta: a Japanese single-centre experience." European Journal of Cardio-Thoracic Surgery 58, no. 3 (April 3, 2020): 590–97. http://dx.doi.org/10.1093/ejcts/ezaa080.

Full text

Abstract:

Abstract OBJECTIVES In this study, we investigated the early and midterm outcomes of initial watch-and-wait strategy for Stanford type A intramural haematoma and acute aortic dissection with thrombosed false lumen of the ascending aorta in patients with a maximum aortic diameter of ≤50 mm, pain score of ≤3/10 and no ulcer-like projection in the ascending aorta. METHODS Inpatient and outpatient records were retrospectively reviewed. RESULTS Of the 81 patients with type A intramural haematoma and acute aortic dissection with the thrombosed false lumen of the ascending aorta between April 2011 and April 2019, a watch-and-wait strategy was selected in 46 patients. The mean age of the patients was 68 years, and 22 (48%) patients were female. Ten patients underwent emergency pericardial drainage for cardiac tamponade at the time of presentation and 8 patients underwent aortic repair during hospitalization for new ulcer-like projection, re-dissection or rupture. In-hospital mortality occurred in 2 (4%) patients. During follow-up, survival at 1 and 2 years was 95% and 92%, respectively. There was no significant difference in survival or aortic events between patients in whom the watch-and-wait strategy and emergency surgical treatment were indicated. CONCLUSIONS The early and midterm outcomes of the initial watch-and-wait strategy were favourable for type A intramural haematoma and acute aortic dissection with the thrombosed false lumen of the ascending aorta in Japanese patients with a maximum aortic diameter of ≤50 mm, pain score of ≤3/10 and no ulcer-like projection. Further study is required to show the safety of this strategy.

APA, Harvard, Vancouver, ISO, and other styles

45

Borodavina, E. V., A. Yu Shurinov, S. I. Kutukova, E. N. Nedozorova, A. V. Malanchuk, Yu V. Semenchenko, S. M. Povarkov, et al. "“Watch and wait” approach in the treatment of advanced radioiodine refractory differentiated thyroid cancer: a study of barriers and drivers of use." Head and Neck Tumors (HNT) 13, no. 4 (April 6, 2024): 73–82. http://dx.doi.org/10.17650/2222-1468-2023-13-4-73-82.

Full text

Abstract:

Introduction. The multikinase inhibitors have demonstrated high clinical efficacy in treatment of the radioiodine refractory differentiated thyroid cancer. At the same time, the inclusion criteria in the studies has reflected a minimum set of characteristics important for beginning of use of these drugs and an approach that takes into account the tumor progression rate (the volume doubling time) in the absence of clinical manifestations of the disease that have made it possible to individualize the start of therapy. Aim. To describe and evaluate the barriers and drivers of use the “watch and wait” approach by Russian oncologists in treatment of the radioiodine refractory thyroid cancer. Materials and methods. We conducted 35 structured interviews with oncologists observing patients after radioiodine therapy in order to evaluate the “watch and wait” approach. unfortunately, data on use and prevalence of this approach in Russia are limited. The present study involved the use of deductive content analysis as well as analysis of implementation model of clinical guidelines and included investigation of issue of implementation of the “watch and wait” approach to current practice of therapy for radioiodine refractory differentiated thyroid cancer. One of the main tasks was to determine the influence of external factors on the treatment of this category of patients. Conclusion. Barriers and drivers of using “watch and wait” approach in the treatment of differentiated radioiodine refractory thyroid cancer are identified at several levels. for wide use of this approach, it is necessary to involve oncologists taking into account their attitude regarding changes in routine practices, patient expectations and to obtain additional data regarding its long-term effectiveness.

APA, Harvard, Vancouver, ISO, and other styles

46

Mehra, Tarun, Judith E. Lupatsch, Thibaud Kössler, Konstantin Dedes, Alexander Reinhard Siebenhüner, Roger von Moos, Andreas Wicki, and Matthias E. Schwenkglenks. "Olaparib not cost-effective as maintenance therapy for platinum-sensitive, BRCA1/2 germline-mutated metastatic pancreatic cancer." PLOS ONE 19, no. 4 (April 4, 2024): e0301271. http://dx.doi.org/10.1371/journal.pone.0301271.

Full text

Abstract:

Objective To assess the cost-effectiveness and budget impact of olaparib as a maintenance therapy in platinum-responsive, metastatic pancreatic cancer patients harboring a germline BRCA1/2 mutation, using the Swiss context as a model. Methods Based on data from the POLO trial, published literature and local cost data, we developed a partitioned survival model of olaparib maintenance including full costs for BRCA1/2 germline testing compared to FOLFIRI maintenance chemotherapy and watch-and-wait. We calculated the incremental cost-effectiveness ratio (ICER) for the base case and several scenario analyses and estimated 5-year budget impact. Results Comparing olaparib with watch-and wait and maintenance chemotherapy resulted in incremental cost-effectiveness ratios of CHF 2,711,716 and CHF 2,217,083 per QALY gained, respectively. The 5-year costs for the olaparib strategy in Switzerland would be CHF 22.4 million, of which CHF 11.4 million would be accounted for by germline BRCA1/2 screening of the potentially eligible population. This would amount to a budget impact of CHF 15.4 million (USD 16.9 million) versus watch-and-wait. Conclusions Olaparib is not a cost-effective maintenance treatment option. Companion diagnostics are an equally important cost driver as the drug itself.

APA, Harvard, Vancouver, ISO, and other styles

47

Azevedo, José Gonçalves Moreira de, Laura Fernandez, Alberto Ignacio Herrando, Inês Santiago, Oriol Pares, and Amjad Parvaiz. "Watch and Wait for rectal cancer in inflammatory bowel disease." BMJ Case Reports 16, no. 7 (July 2023): e252562. http://dx.doi.org/10.1136/bcr-2022-252562.

Full text

Abstract:

Colorectal cancer is currently the third most frequently diagnosed type of cancer and the second cause of cancer death in the western world. Inflammatory bowel disease patients are 2–6 times more likely to develop CRC than the general population. Patients with CRC arising through Inflammatory Bowel Disease have an indication for surgery. However, in patients without Inflammatory Bowel Disease, the use of organ (rectum) preservation strategies after neoadjuvant treatment is on the rise, which means that patients are able to keep the organ without the need for complete excision, either by treatment with radiotherapy and chemotherapy, or in combination with endoscopic or surgical techniques that allow local excision without the need for resection of the entire organ. The patient management approach known as the Watch and Wait programme was first introduced in 2004 by a team from São Paulo, Brazil. This approach suggested that patients who had an excellent or complete clinical response after neoadjuvant treatment could defer surgery and instead undergo Watch and Wait. This organ preservation technique became popular because it allowed patients to avoid the complications associated with major surgery while achieving similar oncological outcomes to those who underwent both neoadjuvant therapy and radical surgery. Following completion of neoadjuvant treatment, a decision to defer surgery is made based on whether a clinical Complete Response can be achieved, which means there is no evidence of tumour in clinical and radiological examination. The International Watch and Wait Database has published long-term oncological outcomes for patients treated with this strategy, and more patients are showing interest in this treatment option. However, it is important to note that up to 1/3 of patients selected for Watch and Wait may eventually require surgery for local regrowth (also known as ‘deferred definitive surgery’) at any time during follow-up after an initial ‘apparent’ clinical Complete Response. Compliance with a strict surveillance protocol ensures early detection of regrowth, which is usually amenable to R0 surgery and provides excellent long-term local disease control. Nonetheless, it is crucial to assess the perioperative consequences of having surgery for regrowth later and whether there are any negative effects from deferring surgery. Currently, the Watch and Wait strategy is recommended in the NCCN guidelines for clinical complete responders and only in specialised multidisciplinary centres.There is no case in the literature that portrays the use of the Watch and Wait programme for patients with inflammatory bowel disease and rectal cancer.The authors intend to present a case that demonstrates the difficulties in the assessment of patients with inflammatory bowel disease, the risks of using radiotherapy in this patients and the challenges of surveillance for patients with colorectal cancer and inflammatory bowel disease.

APA, Harvard, Vancouver, ISO, and other styles

48

&NA;. "Watch and wait policy appropriate in non-Hodgkin's lymphoma." Inpharma Weekly &NA;, no. 1401 (August 2003): 12. http://dx.doi.org/10.2165/00128413-200314010-00029.

Full text

APA, Harvard, Vancouver, ISO, and other styles

49

Pozo, Marcos E. "Watch and wait approach to rectal cancer: A review." World Journal of Gastrointestinal Surgery 7, no. 11 (2015): 306. http://dx.doi.org/10.4240/wjgs.v7.i11.306.

Full text

APA, Harvard, Vancouver, ISO, and other styles

50

Galhotra, Abhiruchi, and Abhisek Mishra. "Mental healthcare Act 2017: Need to wait and watch." International Journal of Applied and Basic Medical Research 8, no. 2 (2018): 67. http://dx.doi.org/10.4103/ijabmr.ijabmr_328_17.

Full text

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!